Potassium Chloride
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
- Potassium Chloride
- Potassium Chloride: From Potassium Supplementation (Hypokalemia) to Renal Tubular Acidosis
Potassium Chloride: From Potassium Supplementation (Hypokalemia) to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride (DrugBank DB00761) is an electrolyte replacement agent conventionally used to treat or prevent hypokalemia. The TxGNN model predicts it may also be relevant to Renal Tubular Acidosis (RTA), a condition frequently accompanied by significant renal potassium wasting. Currently 9 clinical trials and 19 publications touch on this space, but none directly test KCl as an intervention in an RTA population — the supporting evidence is mechanistic/review-level rather than trial-confirmed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium supplementation / hypokalemia (based on general pharmacologic knowledge; no formal indication text available in this dataset) |
| Predicted New Indication | Renal Tubular Acidosis |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for potassium chloride in this dataset. Based on known pharmacology, KCl acts as a direct electrolyte replacement agent that restores extracellular/intracellular potassium balance and supplies chloride to offset anion gap disturbances — it is a supportive/replacement therapy rather than a receptor- or pathway-targeted drug.
Renal tubular acidosis (proximal/type 2, distal/type 1, and type 4) is defined by impaired renal acid-base handling. Type 1 (distal) and type 2 (proximal) RTA commonly cause substantial urinary potassium wasting and resulting hypokalemia, which is exactly the deficiency state KCl is designed to correct. This makes the mechanistic link direct but “supportive” in nature — KCl is not proposed as a novel disease-modifying therapy for RTA, but as a physiologic correction for a downstream consequence of the disease. Notably, type 4 RTA presents with hyperkalemia rather than hypokalemia, meaning KCl would not be appropriate — and could be harmful — in that subtype. Any downstream evaluation must be RTA-subtype-specific.
Clinically, potassium salts (including citrate and bicarbonate forms) are already part of standard supportive care for hypokalemic RTA, which lends real-world plausibility to the TxGNN signal, even though the evidence pack contains no interventional trial testing KCl specifically in this population.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03644706 | Phase 3 | Terminated | 3 | Compared ADV7103 vs. placebo in preventing metabolic acidosis in dRTA; terminated early with only 3 subjects enrolled, not KCl-specific |
| NCT00120731 | N/A | Withdrawn | 0 | Studied potassium citrate (not chloride) in children with hypercalciuria/urolithiasis; withdrawn before enrollment |
| NCT06750172 | N/A | Recruiting | 33 | Diagnostic method comparison for primary aldosteronism; unrelated to KCl treatment |
| NCT07273838 | Phase 2 | Recruiting | 130 | Tests SGLT2 inhibitor in acute cardiorenal syndrome; unrelated to KCl/RTA |
| NCT01834768 | Phase 2 | Unknown | 31 | Eplerenone safety in cyclosporine-treated transplant recipients; indirect electrolyte relevance only |
| NCT01843309 | Phase 4 | Terminated | 36 | Spironolactone to prevent amphotericin B-induced electrolyte abnormalities; terminated, not KCl/RTA |
| NCT01894594 | Phase 1 | Terminated | 7 | Alkali (sodium bicarbonate) therapy in sickle cell disease with low bicarbonate; terminated early, n=7 |
| NCT06867471 | N/A | Recruiting | 43 | Exogenous ketosis effect on proteinuria in CKD/PKD; unrelated to KCl/RTA |
| NCT03354507 | N/A | Unknown | 40 | Sodium bicarbonate alkalinization pilot in children with topiramate-induced RTA; mechanistically related but not KCl, status unknown |
Note: All nine trials above were graded “C” (low direct relevance) in source review — none directly evaluate KCl as an intervention in an RTA population.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33459628 | 2021 | Review | Archivos Españoles de Urología | RTA diagnosis, subtype classification, and management overview, including kidney stone risk |
| 8694660 | 1996 | Review | Archives of Internal Medicine | Pathophysiology and diagnostic approach to RTA subtypes |
| 21314872 | 2011 | Review | International Journal of Clinical Practice | Clinical approach to proximal and distal RTA in adults |
| 3518609 | 1986 | Review | Annual Review of Medicine | Clinical spectrum of RTA across proximal, hypokalemic and hyperkalemic distal subtypes |
| 17297212 | 2007 | Review | Acta Medica Indonesiana | General approach to hypokalemia, including renal causes |
| 38445406 | 2023 | Cohort | La Tunisie Médicale | Genotype-phenotype correlation of distal RTA (hypokalemia, hypercalciuria) |
| 37081692 | 2023 | Classification/Cohort | Endocrine Journal | Reclassifies pseudohypoaldosteronism type II as type IV RTA (hyperkalemic) |
| 25377117 | 2014 | Review | Nephron Physiology | Effect of mineralocorticoids on acid-base and potassium balance |
| 33769949 | 2021 | Review | Journal of the American Society of Nephrology | Reassessment of urine anion gap as a marker in metabolic acidosis |
| 40288831 | 2025 | Case Report | Nefrología | Primary RTA during pregnancy and perinatal outcomes |
India Market Information
No marketing authorization or product registration was found for potassium chloride in this dataset (market status: Not Marketed, 0 total registrations recorded).
Safety Considerations
Drug Interactions (548 total interactions on file; representative Major/Moderate examples):
- Potassium-sparing agents / RAAS blockers (Amiloride, Benazepril, Olmesartan, Valsartan, Aliskiren) — Major, risk of hyperkalemia when combined with KCl supplementation
- Anticholinergic agents (Atropine, Hyoscyamine, Homatropine, Biperiden, Benzatropine, Glycopyrronium) — Major, reduced GI motility may increase risk of solid-dosage-form KCl causing GI mucosal injury
- Antihistamines (Chlorpheniramine, Acrivastine, Phenyltoloxamine, Brompheniramine) — Major, anticholinergic-mediated GI transit slowing
- NSAIDs (Ketorolac, Ibuprofen) — Moderate, risk of hyperkalemia and reduced renal potassium excretion
- Amitriptyline — Major, anticholinergic GI effect
Formal TFDA label warnings and contraindications are not yet available in this dataset (flagged as a Blocking data gap — see Conclusion below); prescribing decisions should not rely on this report alone until that data is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The current evidence is L4 (mechanism/review-level): no completed trial directly tests KCl in an RTA population, and the nine identified trials were all graded low direct relevance (several terminated/withdrawn or testing unrelated agents).
- Official TFDA label data (warnings/contraindications) is marked as a Blocking data gap, meaning the S1 safety pre-screen cannot yet be completed.
- The drug has no marketed registration in this jurisdiction (0 licenses), and RTA is subtype-heterogeneous — type 4 RTA involves hyperkalemia, where KCl would be inappropriate, so any future guardrail must include subtype-level exclusion criteria.
To proceed, the following is needed:
- Retrieve and parse the TFDA label (or equivalent reference labeling) for formal warnings/contraindications
- Confirm applicability strictly to hypokalemic RTA subtypes (type 1/type 2), explicitly excluding type 4 RTA
- Seek RTA-specific supportive-care literature/guidelines on potassium salt use (current dataset only supports general RTA pathophysiology, not KCl intervention outcomes)
- Re-run evidence review once safety data gap is resolved, and reconsider “Proceed with Guardrails” at that point
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.